News
Re-Vana Announces Two New Team Appointments
RE-Vana Therapeutics CEO Michael J. O'Rourke announces two new team appointments: Following our successful $11.9M Series A in November 2022, Re-Vana Therapeutics is delighted to further strengthen our team with two new appointments as we develop our sustained release...
Re-Vana Therapeutics Raises $11.9 Million in Series A Financing
Visionary Ventures Leads Financing Round to Support the Development of Sustained Release Ophthalmic Therapeutics BELFAST, Northern Ireland, Nov. 30, 2022 /PRNewswire/ -- Re-Vana Therapeutics Ltd, a privately-held specialty drug delivery company...
Re-Vana Therapeutics wins the Business Innovation Award, sponsored by Belfast City Council
Next up we have the Business Innovation Award, sponsored by Belfast City Council. The winner is Re Vana Therapeutics for their outstanding work on the treatment of chronic eye diseases. @re_vana @belfastcc#BelfastBusinessAwards...
Re-Vana Therapeutics win the “Retina Innovation Award’ in Drug Delivery at the OIS Retina Summit
Re-Vana Therapeutics win the "Retina Innovation Award' in Drug Delivery at the OIS Retina Summit - New York 13th July 2022 https://ois.net/ois-retina-innovation-summit-2022/ Michael O'Rourke pictured with the the ExSight Ventures team - Firas Rahhal M.D.,...
CEO Michael O’Rourke presents at the OIS Drug Delivery Forum December 2021
The OIS Drug Delivery Forum was held virtually on December 2, 2021. Re-Vana CEO Michael O'Rourke delivered a virtual presentation about the Re-Vana technology. See the video on Vimeo by following this link, or watch it embedded below....
Q&A with Michael J. O’Rourke, Chief Executive Officer at Re-Vana Therapeutics, which is developing sustained release biologics and small molecule drugs for the eye.
The purpose of article series from AdLib, ‘Product | People | Potential’ is to feature and showcase the very best UK start-ups with great potential, truly inspiring businesses that are shaking up their sector. We capture and share the stories behind the name. We...
Securing Early-Stage Funding for Retinal Innovations – ASRS Retina Times Summer 20212 Publication with contribution from CEO Michael O’Rourke
In the first 2 articles of the Retina Times Innovation and Entrepreneurship section, we discussed how to secure your intellectual property (IP), define your business model, assemble your team, and develop a quality management system (QMS). Here, we discuss fund...
Sophie Bakri MD, Chair of the Department of Ophthalmology at Mayo Clinic, Rochester, MN joins Re-Vana Scientific Advisory Board
Sophie Bakri MD, Chair of the Department of Ophthalmology at Mayo Clinic, Rochester, MN joins Re-Vana Scientific Advisory Board
Re-Vana Therapeutics Strengthens Executive Team with the Appointments of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of R&D
New Appointments Bring Extensive Ocular Drug Delivery, Strategy and Scientific Expertise to Advance the Sustained Release of Biologics and Small Molecules into the Eye to Treat Sight-Threatening Eye Diseases Belfast, Northern Ireland – 23 February 2021 – Re-Vana...
ExSight Ventures discuss why they invested into Re-Vana
In the OIS Podcast, ExSight Ventures discuss why they invested into Re-Vana. Here is the segment where they discuss Re-Vana Therapeutics: Download the excerpt using this link.Listen to the Full Podcast Here (Discussion of Re-Vana commences at 43 minutes.)...
Michael O’Rourke CEO presents online at the OIS Drug Delivery Forum – 5th November 2020
Michael O’Rourke CEO presents online at the OIS Drug Delivery Forum – 5th November 2020